Sepantronium bromide (YM155) 与 γ 辐射结合显示出有效的抗肿瘤活性针对裸鼠中的 H460 或 Calu6 异种移植物 。 在这种原位肾和转移性肺肿瘤模型中，Sepantronium bromide (YM-155) 和 IL-2 相加地降低了肿瘤重量、肺转移和荧光素染色的肿瘤图像 [3] 。

2007年9月1日 · Various accumulating evidence suggests that survivin, a member of the inhibitor of apoptosis (IAP) family, plays an important role in drug resistance and cancer cell survival in many types of cancer, including hormone-refractory prostate cancer (HRPC). Here, we characterized YM155, a novel small-mol …

2022年7月30日 · The imidazolium compound Ym155 was first reported to be a survivin inhibitor. Ym155 potently induces cell death of many types of cancer cells in preclinical studies.

2023年2月1日 · In our study, YM155 specifically inhibited MNA neuroblastoma cell growth in vitro and significantly inhibited tumor growth in vivo, indicating that patients with high-risk MYCN-driven neuroblastoma would likely benefit from YM155 treatment. More importantly, this drug may be applicable in other tumor types in which MYCN is the driving oncogene.

2018年7月6日 · YM155, a small molecule inhibitor of survivin, was previously shown to potently inhibit the viability of immortalized and patient derived renal cell carcinoma (RCC) cell...

YM155 (YM-155, Sepantronium Bromide) 是一种新型的小分子survivin抑制剂 （生存素抑制剂、存活素抑制剂） ，IC 50 为0.54 nM，通过抑制survivin基因启动子转录从而抑制survivin表达，而不会显著抑制SV40启动子活性。

2023年4月5日 · Based on its structural similarity to the GBM-selective prodrug RIPGBM, here, we report the design, synthesis, and characterization of a prodrug form of YM155, termed aYM155. aYM155 displays potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells (IC 50 = 0.7-10 nM), as well as EGFR-amplified and EGFR ...

YM155, a small molecule inhibitor of the antiapoptotic protein survivin, has been developed as a potential anti-cancer drug. We investigated a combination therapy of YM155 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). YM155 caused cell cycle arrest and apoptosis in renal cancer (RENCA) cells.

YM155是一种通过对生存素表达的功能抑制剂进行表型筛选而获得的高效广谱抗癌药物，但其相关的生物分子靶点目前仍然未知。 由于缺乏对细胞类型的选择性，因此YM155在临床应用中仍会遇到耐受性问题。 基于其与GBM选择性前药RIPGBM的结构相似性，斯克利普斯研究所Luke L. Lairson和斯坦福大学Paul S. Mischel设计、合成并表征了一种YM155前药（aYM155）。 本文要点： （1）研究发现，aYM155能够对多种患者源性GBM癌症干细胞样细胞 (IC50 = 0.7 ~ 10 nM) …

2015年4月22日 · YM155 (sepantronium bromide) is a small molecule originally discovered as a suppressant of survivin expression [12]. YM155 has shown potent antiproliferative effects on a variety of human cancer cell lines [13]. Although no human trials have been designed to test this drug in ALL, it has theoretical potential for clinical benefit.